ARCHIVES

FDA advisors vote against recommending Johnson & Johnson’s Zarnestra for treatment of AML in the elderly.

This article is from The Cancer Letter archive.

Vol. 31 No. 18 | May 6, 2005

Download PDF Visit The Full Archive

Related Articles

FDA Issues MedWatch Warning, Begins Safety Review Of Prostate Cancer Drugs

May 7, 2010

Last Issue Until Aug. 20

July 30, 1982

In Brief: Thomas Davis Is Named New Director Of NCCP; Senate Subcommittee Give NCI $1.2 Bil. For FY ‘86

September 27, 1985

Conversation with The Cancer Letter: Daniel Hayes Leads Tour of Caris Website

August 8, 2014

Hoogstraten Resignation Sidetracks Kansas’ Move to Comprehensive Status, Threatens Core Grant

February 15, 1980

ASCO, ONS Issue Standards For Safe Chemotherapy Administration

October 2, 2009